Phase 2b Trial of Pirepemat, to Prevent Falls, Approved in Sweden

Phase 2b Trial of Pirepemat, to Prevent Falls, Approved in Sweden

315012

Phase 2b Trial of Pirepemat, to Prevent Falls, Approved in Sweden

IRLAB has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2b trial for its investigational medication, pirepemat (previously known as IRL752), which is intended to treat impaired balance and prevent falls in patients with Parkinson’s disease. “Pirepemat has potential to be the first treatment in a new class of drugs designed to improve balance and reduce fall injuries in people living with Parkinson’s disease,” Nicholas Waters, CEO at IRLAB, said in…

You must be logged in to read/download the full post.